Sector | Healthcare |
Industry | - |
Day Range | 18.02 | 18.75 |
52-Wk Range | - | - |
Last Close | 18.27 |
Mkt Cap (m) | 1,016.87 |
Dividend yield | - |
ISIN | US98978L2043 |
Volume | 518,625.00 |
Exchange Venue | NAS |
Zogenix Inc is a pharmaceutical company engaged in commercializing and developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.
Price/Earning | - |
Price/Book | 2.41 |
Price/Sales | 131.19 |
P/CF | - |
Rev Growth (3 year avg) | - |
EPS Growth (3 year avg) | - |
Operating Margin % | - |
Net Margin % | - |
Return on Equity | - |
Debt/Equity | - |
en 04/03/2020 |
en 31/12/2019 |
Please refer to the below issuer website for further documents.
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 27.18 | 28.85 | 9.82 | 0.00 | 3.65 | - |
Operating Income (m) | -49.73 | -62.45 | -94.24 | -139.88 | -172.78 | - |
Net Income (m) | 26.14 | -69.71 | -126.82 | -123.91 | -419.50 | - |
Basic EPS | 1.22 | -2.81 | -4.65 | -3.27 | -9.74 | - |
Avg. Diluted Shares Outstanding (m) | 21.45 | 24.79 | 27.30 | 37.88 | 43.08 | - |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 184.60 | 119.91 | 304.70 | 532.73 | 287.24 | - |
Non Current Assets (m) | 121.39 | 111.59 | 112.91 | 115.60 | 127.01 | - |
Total Assets (m) | 305.99 | 231.51 | 417.61 | 648.33 | 414.25 | - |
Current Liabilities (m) | 30.08 | 20.31 | 20.98 | 58.38 | 95.39 | - |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | 182.76 | 120.76 | 301.52 | 522.80 | 245.06 | - |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | -64.60 | -72.88 | -75.87 | -111.66 | -111.52 | - |
Capital Expenditure (m) | -0.31 | -0.10 | -0.08 | -1.02 | -9.49 | - |